In contrast to reports of lower frequency of peripheral CD4+ T cells in breast cancer patients, almost all studies have found no significant difference in the frequency of peripheral CD19+ B cells between cancer patients and healthy controls. This evidence concerns the gene CD4 and breast carcinoma.